dbo:abstract
|
- Daridorexant ist ein Arzneistoff aus der Gruppe der Orexinrezeptor-Antagonisten. Er wurde in den USA im Januar 2022 und in der EU im April 2022 unter dem Namen Quviviq zur Behandlung von Schlafstörungen zugelassen. Das Mittel wird oral gegeben. (de)
- Daridorexant, sold under the brand name Quviviq, is an orexin antagonist medication which is used for the treatment of insomnia. Daridorexant is taken by mouth. Side effects of daridorexant include headache, somnolence, and fatigue. The medication is a dual orexin receptor antagonist (DORA). It acts as a selective dual antagonist of the orexin receptors OX1 and OX2. Daridorexant has a relatively short elimination half-life of 8 hours and a time to peak of about 1 to 2 hours. It is not a benzodiazepine or Z-drug and does not interact with GABA receptors, instead having a distinct mechanism of action. Daridorexant was approved for medical use in the United States in January 2022 and became available in May 2022. It was approved in the European Union in April 2022, and is the first orexin receptor antagonist to become available in European Union. The medication is a schedule IV controlled substance in the United States and may have a modest potential for misuse. (en)
- Даридорексант — антагонист орексиновых рецепторов, используемый как снотворное средство. Одобрен для применения: США (2022). (ru)
|
dbo:alternativeName
| |
dbo:bioavailability
| |
dbo:casNumber
|
- 1505484-82-1
- 1792993-84-0
|
dbo:chEMBL
| |
dbo:class
| |
dbo:drugbank
| |
dbo:fdaUniiCode
| |
dbo:kegg
| |
dbo:pubchem
| |
dbo:thumbnail
| |
dbo:wikiPageExternalLink
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 39081 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:atcPrefix
| |
dbp:bioavailability
| |
dbp:c
| |
dbp:casNumber
|
- 1505484 (xsd:integer)
- 1792993 (xsd:integer)
|
dbp:chembl
|
- 4297590 (xsd:integer)
- 4650216 (xsd:integer)
|
dbp:chemspiderid
| |
dbp:cl
| |
dbp:class
| |
dbp:dailymedid
| |
dbp:drugbank
| |
dbp:durationOfAction
| |
dbp:eliminationHalfLife
| |
dbp:excretion
|
- Feces: ~57% (en)
- Urine: ~28% (en)
|
dbp:h
| |
dbp:index2Label
| |
dbp:iupacName
|
- [-2--2-methylpyrrolidin-1-yl]-[5-methoxy-2-phenyl]methanone (en)
|
dbp:iupharLigand
| |
dbp:kegg
| |
dbp:legalEu
| |
dbp:legalUs
| |
dbp:metabolism
| |
dbp:n
| |
dbp:o
| |
dbp:onset
| |
dbp:pdbLigand
| |
dbp:proteinBound
| |
dbp:pubchem
|
- 91801202 (xsd:integer)
- 91809208 (xsd:integer)
|
dbp:routesOfAdministration
| |
dbp:smiles
| |
dbp:stdinchi
| |
dbp:stdinchikey
|
- NBGABHGMJVIVBW-QHCPKHFHSA-N (en)
|
dbp:synonyms
|
- Nemorexant; ACT-541468 (en)
|
dbp:tradename
| |
dbp:unii
|
- 9 (xsd:integer)
- LMQ24G57E9 (en)
|
dbp:usan
|
- Daridorexant hydrochloride (en)
|
dbp:width
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
rdf:type
| |
rdfs:comment
|
- Daridorexant ist ein Arzneistoff aus der Gruppe der Orexinrezeptor-Antagonisten. Er wurde in den USA im Januar 2022 und in der EU im April 2022 unter dem Namen Quviviq zur Behandlung von Schlafstörungen zugelassen. Das Mittel wird oral gegeben. (de)
- Даридорексант — антагонист орексиновых рецепторов, используемый как снотворное средство. Одобрен для применения: США (2022). (ru)
- Daridorexant, sold under the brand name Quviviq, is an orexin antagonist medication which is used for the treatment of insomnia. Daridorexant is taken by mouth. Side effects of daridorexant include headache, somnolence, and fatigue. The medication is a dual orexin receptor antagonist (DORA). It acts as a selective dual antagonist of the orexin receptors OX1 and OX2. Daridorexant has a relatively short elimination half-life of 8 hours and a time to peak of about 1 to 2 hours. It is not a benzodiazepine or Z-drug and does not interact with GABA receptors, instead having a distinct mechanism of action. (en)
|
rdfs:label
|
- Daridorexant (en)
- Daridorexant (de)
- Даридорексант (ru)
|
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:depiction
| |
foaf:isPrimaryTopicOf
| |
is dbo:product
of | |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is dbp:products
of | |
is foaf:primaryTopic
of | |